ArticleEMBO molecular medicine2016
Concise gene signature for point-of-care classification of tuberculosis.
Article in EMBO molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.PLoS computational biology · 2023Pooled it
- Increasing reproducibility, robustness, and generalizability of biomarker selection from meta-analysis using Bayesian methodology.PLoS computational biology · 2022Pooled it
- Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis.The Lancet. Respiratory medicine · 2020Pooled it
- Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures.PLoS medicine · 2019Pooled it
- Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis.The Lancet. Respiratory medicine · 2016Pooled it
- Blood transcriptomic signatures predict poor outcomes in drug-susceptible pulmonary tuberculosis in Brazil.American journal of respiratory and critical care medicine · 2026Article
- Inflammatory biomarkers of asymptomatic and symptomatic tuberculosis.Nature communications · 2026Article
- RISK6 as a Translational Host Transcriptomic Signature for Tuberculosis Diagnosis, Treatment Monitoring, and Risk Stratification.Pathogens (Basel, Switzerland) · 2026Review
- Neutrophil-specific transcriptomic profiling reveals a novel signature for active tuberculosis diagnosis.Microbiology spectrum · 2026Article
- PTBD: a machine learning-based non-invasive diagnostic model for pulmonary tuberculosis using large-scale blood transcriptomes.BMC biology · 2026Article
- Machine-Learning-Derived, Mechanistically Informed Transcriptomic Signature to Diagnose Active Tuberculosis and Guide Host-Directed Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- Host- and pathogen-related determinants of pulmonaryEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Deep immune profiling delineates hallmarks of disease heterogeneity in extrapulmonary tuberculosis.Nature communications · 2025Article
- Inflammatory Biomarkers of Asymptomatic and Symptomatic Tuberculosis.bioRxiv : the preprint server for biology · 2025Article
- Blood transcriptomic signatures predict poor treatment outcomes in drug-susceptible pulmonary TB in Brazil.medRxiv : the preprint server for health sciences · 2025Article
- International multicenter development of ensemble machine learning driven host response based diagnosis for tuberculosis.iScience · 2025Article
- Potential auxiliary diagnostic role of pentraxin 3 in plasma and bronchoalveolar lavage fluid for pulmonary tuberculosis.Journal of cardiothoracic surgery · 2025Article
- Bridging science and policy in tuberculosis treatment through innovations in precision medicine, drug development, and cohort research: a narrative review.Ewha medical journal · 2025Review
- Cross-species transcriptomics translation reveals a role for the unfolded protein response in Mycobacterium tuberculosis infection.NPJ systems biology and applications · 2025Article
- Evaluation of host-immune biomarker signatures as multiplex qPCR diagnostic assays: a pilot study toward meeting WHO target product profiles for TB diagnosis in India.Frontiers in tuberculosis · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an urgent need for new tools to combat the ongoing tuberculosis (TB) pandemic. Gene expression profiles based on blood signatures have proved useful in identifying genes that enable classification of TB patients, but have thus far been complex. Using real-time PCR analysis, we evaluated the expression profiles from a large panel of genes in TB patients and healthy individuals in an Indian cohort. Classification models were built and validated for their capacity to discriminate samples from TB patients and controls within this cohort and on external independent gene expression datasets. A combination of only four genes distinguished TB patients from healthy individuals in both cross-validations and on separate validation datasets with very high accuracy. An external validation on two distinct cohorts using a real-time PCR setting confirmed the predictive power of this 4-gene tool reaching sensitivity scores of 88% with a specificity of around 75%. Moreover, this gene signature demonstrated good classification power in HIV(+) populations and also between TB and several other pulmonary diseases. Here we present proof of concept that our 4-gene signature and the top classifier genes from our models provide excellent candidates for the development of molecular point-of-care TB diagnosis in endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.